470: Everolimus Reduces the Risk of Humoral Rejection in...

470: Everolimus Reduces the Risk of Humoral Rejection in De-Novo HTx Recipients Compared to MMF Treated Patients

H.B. Lehmkuhl, N.E. Hiemann, M. Dandel, D. Mai, C. Knosalla, O. Grauhan, R. Meyer, M. Pasic, M. Huebler, Y. Weng, R. Hetzer
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Year:
2008
Language:
english
DOI:
10.1016/j.healun.2007.11.483
File:
PDF, 63 KB
english, 2008
Conversion to is in progress
Conversion to is failed